Peritoneal Dialysis-related Infection
Conditions
Keywords
Peritoneal dialysis-related infection, Infectious peritonitis, Exit-site infection, Infection rate, Drug susceptibility
Brief summary
Peritoneal dialysis-related infection is a complication that leads to peritoneal dialysis catheter removal or patient death. The present study aimed to investigate peritoneal dialysis-related infection, causative pathogens resulting in topical 2% mupirocin ointments period compare with 0.1% gentamicin cream period. Rate of catheter removal, time to first peritoneal dialysis-related infection after apply gentamicin cream.
Interventions
DRUGGentamicin
Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
DRUGMupirocin
Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021
Sponsors
Silpakorn University
Phramongkutklao College of Medicine and Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Single group: topical mupirocin ointment retrospective period compare with gentamicin prospective period
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age greater than or equal to 20 years * End stage renal disease patients on peritoneal dialysis follow up at Phramongkutklao hospital's peritoneal dialysis clinic between January 1, 2021 to March 31, 2023 * Start peritoneal dialysis or follow up at Phramongkutklao hospital's peritoneal dialysis clinic at least 90 days before recruited * Use topical mupirocin ointment for prevention of peritoneal dialysis-related infection between January 1, 2021 to December 31, 2021 * Can be used LINE application throughout the study
Exclusion criteria
* Allergy to gentamicin or components * Previous systemic antibiotics use within 90 days before recruited * Previous peritoneal dialysis-related infection within 28 days before recruited * Immunosuppressants used * Prospective follow up less than 2 months * Don't sign informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Exit-site infection in mupirocin compared with gentamicin group | All exit-site infection episodes occurred last year in mupirocin group and all exit-site infection episodes have occurred after apply 0.1% grntamicin cream for 1 year. | Exit-site infection diagnosis by physician. Retrospective data collection from patient's medical records in mupirocin group Prospective data collection from patient's medical records in gentamicin group. |
| Rate of Infectious peritonitis in mupirocin compared with gentamicin group | All infectious peritonitis episodes occurred last year in mupirocin group and all infectious peritonitis episodes have occurred after apply 0.1% grntamicin cream for 1 year. | Infectious peritonitis diagnosis by physicians. Retrospective data collection from patient's medical records in mupirocin group Prospective data collection from patient's medical records in gentamicin group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of catheter removal due to peritoneal dialysis-related infection | Retrospective period at least 1 year before recruit to the study, Prospective period at least 1 year after entry to the study. | Prospective data collection from patient's medical records in gentamicin group |
| Number and percentage Causative pathogens of Exit-site infection in mupirocin compared with gentamicin group | All pathogenic organisms of exit-site infection episodes occurred last year in mupirocin group and all pathogenic organisms of exit-site infection episodes have occurred after apply 0.1% grntamicin cream for 1 year. | Retrospective data collection from patient's medical records in mupirocin group Prospective data collection from patient's medical records in gentamicin group |
| Drug susceptibility of causative pathogens of peritoneal dialysis-related infection | Retrospective period at least 1 year before recruit to the study, Prospective period at least 1 year after entry to the study. | Drug susceptibility test by broth micro-dilution and E-test. Retrospective data collection from patient's medical records in mupirocin group Prospective data collection from patient's medical records in gentamicin group |
| Time to first peritoneal dialysis-related infection after gentamicin application | Prospective period at least 1 year after entry to the study. | Retrospective data collection from patient's medical records in mupirocin group Prospective data collection from patient's medical records in gentamicin group. Peritoneal-related infection diagnosis by physicians. Prospective data collection from patient's medical records in gentamicin group |
| Number and percentage Causative pathogens of Infectious peritonitis in mupirocin compared with gentamicin group | All pathogenic organisms of infectious peritonitis episodes occurred last year in mupirocin group and all pathogenic organisms of infectious peritonitis episodes have occurred after apply 0.1% grntamicin cream for 1 year. | Retrospective data collection from patient's medical records in mupirocin group Prospective data collection from patient's medical records in gentamicin group |
Countries
Thailand
Contacts
Primary ContactIttaprach Yimsuk, PharmD
Backup ContactPamila Tasanavipas, MD
Outcome results
None listed